Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease

Mod Rheumatol. 2018 Jul;28(4):724-729. doi: 10.3109/14397595.2016.1153443. Epub 2016 Mar 11.

Abstract

Interstitial lung disease (ILD) with dermatomyositis often requires intensive immunosuppressive therapy. Here, we report two cases of pulmonary alveolar proteinosis (PAP) in dermatomyositis with ILD. One case was secondary PAP, and the other was autoimmune PAP positive for the anti-granulocyte macrophage-colony-stimulating factor antibody. PAP arose during immunosuppressive therapy and symptoms ceased by attenuating immunosuppression. Exacerbation of pulmonary lesions during intensive immunosuppressive therapy may distinguish PAP from worsening ILD and attenuating immunosuppression should be considered.

Keywords: Dermatomyositis; Granulocyte macrophage–colony-stimulating factor; Immunosuppression; Pulmonary alveolar proteinosis.

Publication types

  • Case Reports

MeSH terms

  • Dermatomyositis / drug therapy*
  • Dermatomyositis / immunology
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / immunology
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases, Interstitial / drug therapy*
  • Lung Diseases, Interstitial / immunology
  • Middle Aged
  • Pulmonary Alveolar Proteinosis / etiology*
  • Pulmonary Alveolar Proteinosis / pathology

Substances

  • Immunosuppressive Agents
  • Granulocyte-Macrophage Colony-Stimulating Factor